Lakshmi Selvaratnam

Lakshmi Selvaratnam

Auto-generated profile, based on publicly available information

Lakshmi Selvaratnam

Monash University

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2011 in Journal of Orthopaedic Research
Verified
Journal Article
Open access
PDF file
PCPan‐Pan Chong
Pan‐Pan Chong
LSLakshmi Selvaratnam
Lakshmi Selvaratnam
AAAzlina Amir Abbas
Azlina Amir Abbas
TKTunku Kamarul
Tunku Kamarul
The use of mesenchymal stem cells (MSCs) for cartilage repair has generated much interest owing to their multipotentiality. However, their significant presence in peripheral blood (PB) has been a matter of much debate. The objectives of this study are to isolate and characterize MSCs derived from PB and, compare their chondrogenic potential to MSC derived from bone marrow (BM). PB and BM derived MSCs from 20 patients were isolated and characterized. From 2 ml of PB and BM, 5.4 ± 0.6 million and 10.5 ± 0.8 million adherent cells, respectively, were obtained by cell cultures at passage 2. Both PB and BM derived MSCs were able to undergo tri‐lineage differentiation and showed negative expression of CD34 and CD45, but positively expressed CD105, CD166, and CD29. Qualitative and quantitative examinations on the chondrogenic potential of PB and BM derived MSCs expressed similar cartilage specific gene (COMP) and proteoglycan levels, respectively. Furthermore, the s‐GAG levels expressed by chondrogenic MSCs in cultures were similar to that of native chondrocytes. In conclusion, this study demonstrates that MSCs from PB maintain similar characteristics and have similar chondrogenic differentiation potential to those derived from BM, while producing comparable s‐GAG expressions to chondrocytes. © 2011 Orthopaedic Research Society. © 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 30:634–642, 2012

20 March 2013 in Journal of Anatomy
Verified
Journal Article
Open access
PDF file
Sik Loo TanSik Loo Tan
Sik Loo Tan
TATunku Sara Ahmad
Tunku Sara Ahmad
LSLakshmi Selvaratnam
Lakshmi Selvaratnam
TKTunku Kamarul
Tunku Kamarul
Mesenchymal stem cells (MSCs) are recognized by their plastic adherent ability, fibroblastic‐like appearance, expression of specific surface protein markers, and are defined by their ability to undergo multi‐lineage differentiation. Although rabbit bone marrow‐derived MSCs (rbMSCs) have been used extensively in previous studies especially in translational research, these cells have neither been defined morphologically and ultrastructurally, nor been compared with their counterparts in humans in their multi‐lineage differentiation ability. A study was therefore conducted to define the morphology, surface marker proteins, ultrastructure and multi‐lineage differentiation ability of rbMSCs. Herein, the primary rbMSC cultures of three adult New Zealand white rabbits (at least 4 months old) were used for three independent experiments. rbMSCs were isolated using the gradient‐centrifugation method, an established technique for human MSCs (hMSCs) isolation. Cells were characterized by phase contrast microscopy observation, transmission electron microscopy analysis, reverse transcriptase‐polymerase chain reaction (PCR) analysis, immunocytochemistry staining, flow cytometry, alamarBlue® assay, histological staining and quantitative (q)PCR analysis. The isolated plastic adherent cells were in fibroblastic spindle‐shape and possessed eccentric, irregular‐shaped nuclei as well as rich inner cytoplasmic zones similar to that of hMSCs. The rbMSCs expressed CD29, CD44, CD73, CD81, CD90 and CD166, but were negative (or dim positive) for CD34, CD45, CD117 and HLD‐DR. Despite having similar morphology and phenotypic expression, rbMSCs possessed significantly larger cell size but had a lower proliferation rate as compared with hMSCs. Using established protocols to differentiate hMSCs, rbMSCs underwent osteogenic, adipogenic and chondrogenic differentiation. Interestingly, differentiated rbMSCs demonstrated higher levels of osteogenic (Runx2) and chondrogenic (Sox9) gene expressions than that of hMSCs (P < 0.05). There was, however, no difference in the adipogenic (Pparγ) expressions between these cell types (P > 0.05). rbMSCs possess similar morphological characteristics to hMSCs, but have a higher potential for osteogenic and chondrogenic differentiation, despite having a lower cell proliferation rate than hMSCs. The characteristics reported here may be used as a comprehensive set of criteria to define or characterize rbMSCs.

1 July 2009 in Acta Biomaterialia
Verified
Journal Article
Closed access
SLSi Yuen Lee
Si Yuen Lee
BPBarry P. Pereira
Barry P. Pereira
NYN. Yusof
N. Yusof
LSL. Selvaratnam
L. Selvaratnam
ZYZou Yu
Zou Yu
TKTunku Kamarul
Tunku Kamarul

13 September 2011 in The American Journal of Sports Medicine
Verified
Journal Article
Closed access
LTLiang Xin Tay
Liang Xin Tay
RARaja Elina Ahmad
Raja Elina Ahmad
HDHavva Dashtdar
Havva Dashtdar
KTK.W. Tay
K.W. Tay
TMT. Masjuddin
T. Masjuddin
TKTunku Kamarul
Tunku Kamarul
Background: Mesenchymal stem cells (MSCs) represent a promising alternative form of cell-based therapy for cartilage injury. However, the capacity of MSCs for chondrogenesis has not been fully explored. In particular, there is presently a lack of studies comparing the effectiveness of MSCs to conventional autologous chondrocyte (autoC) treatment for regeneration of full-thickness cartilage defects in vivo. Hypothesis: Treatment with allogenic undifferentiated MSCs (alloMSCs) results in superior cartilage tissue regeneration profiles when compared with autoC for repair of focal articular cartilage defects. Study Design: Controlled laboratory study. Methods: Full-thickness articular cartilage defects were created on the weightbearing surface of the medial femoral condyles in both knees of New Zealand White rabbits (N = 30). Six weeks after the defect was induced, the right knee was treated with either alloMSCs (n = 12) or autoC (n = 18), while the left knee remained untreated (control). The rabbits were sacrificed at 6 months after treatment for assessment of cartilage tissue regeneration, which included the Brittberg morphologic score, histologic grading by O’Driscoll score, and quantitative analysis of glycosaminoglycans per total protein content. Results: Apart from significantly higher Brittberg scores in the alloMSC treatment group (8.8 ± 0.8) versus the autoC treatment group (6.6 ± 0.8) (P = .04), both treatments showed similar cartilage regenerative profiles. All outcome measures were significantly higher in the treatment groups compared with their respective controls (P < .05). Conclusion: AlloMSCs have similar effectiveness as autoC for repair of focal cartilage defects. Both treatments resulted in superior tissue regeneration compared with untreated defects. Clinical Relevance: The results have an implication of supporting the potential use of MSCs for cartilage repair after sports injuries or diseases, in view of similar efficacy but less patient morbidity and potential cost savings as compared with conventional autoC therapy.

26 March 2019 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
ZRZulaika Roslan
Zulaika Roslan
MMMudiana Muhamad
Mudiana Muhamad
LSLakshmi Selvaratnam
Lakshmi Selvaratnam
SASharaniza Ab-Rahim
Sharaniza Ab-Rahim
Low-density lipoprotein receptor (LDLR) has been an object of research since the 1970s because of its role in various cell functions. The LDLR family members include LRP5, LRP6, and LRP8. Even though LRP5, 6, and 8 are in the same family, intriguingly, these three proteins have various roles in physiological events, as well as in regulating different mechanisms in various kinds of cancers. LRP5, LRP6, and LRP8 have been shown to play important roles in a broad panel of cancers. LRP5 is highly expressed in many tissues and is involved in the modulation of glucose-induced insulin secretion, bone development, and cholesterol metabolism, as well as cancer progression. Recently, LRP5 has also been shown to play a role in chondroblastic subtype of osteosarcoma (OS) and prostate cancer and also in noncancer case such as osteoporosis. LRP6, which has been previously discovered to share the same structures as LRP5, has also been associated with many cancer progressions such as human triple negative breast cancer (TNBC), primary chronic lymphocytic leukemia (CLL), nonsmall cell lung cancer (NSCL), lung squamous cell carcinoma (LSCC), and hepatocellular carcinoma (HCC). In addition to its role in cancer progression, LRP8 (apolipoprotein E receptor 2 [APOER2]) has also been demonstrated to regulate canonical Wnt/β-catenin signaling pathway whereby this pathway plays a role in cell migration and development. Therefore, this review aimed to elucidate the role of LRP 5, 6, and 8 in regulating the cancer progression.

22 October 2013 in Knee Surgery, Sports Traumatology, Arthroscopy
Verified
Journal Article
Closed access
PDF file
HDHavva Dashtdar
Havva Dashtdar
MMMalliga Raman Murali
Malliga Raman Murali
AAAzlina Amir Abbas
Azlina Amir Abbas
ASAbdulrazzaq Mahmod Suhaeb
Abdulrazzaq Mahmod Suhaeb
LSLakshmi Selvaratnam
Lakshmi Selvaratnam
TKTunku Kamarul
Tunku Kamarul